Clinical Trial Update: Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy, safety, and tolerability of ISIS 304801 in partial lipodystrophy with an open-label extension; results completed and posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lipodystrophy

Drugs mentioned

• ISIS 304801

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Lipodystrophy | Phase 2 | Status: COMPLETED | Results posted: 2020-10-20